Efficacy, safety and pharmacokinetics of atazanavir (200 mg twice daily) plus raltegravir (400 mg twice daily) dual regimen in the clinical setting

详细信息    查看全文

• 作者：Letizia Marinaro^a ; ^{letizia.marinaro@gmail.com} ; Andrea Calcagno^a ; ^{andrea.calcagno@unito.it} ; Diego Ripamonti^b ; ^{diego.ripamonti@hotmail.com} ; Giovanni Cenderello^c ; ^{giovanni.cenderello@galliera.it} ; Veronica Pirriatore^a ; ^{veronica_pirriatore@hotmail.com} ; Laura Trentini^a ; ^{lauratrentini@yahoo.it} ; Bernardino Salassa^a ; ^{salassa@aslto2.piemonte.it} ; ^{bernardino.salassa@aslto2.piemonte.it} ; Caterina Bramato^a ; ^{bramato@tiscali.it} ; Giancarlo Orofino^d ; ^{orofino@aslto2.piemonte.it} ; Antonio D&rsquo ; Avolio^a ; ^{antonio.davolio@unito.it} ; Marco Rizzi^b ; ^{mrizzi@hpg23.it} ; Giovanni Di Perri^a ; ^{giovanni.diperri@unito.it} ; Stefano Rusconi^e ; ^{stefano.rusconi@unimi.it} ; Stefano Bonora^a ; ^{stefano.bonora@unito.it}
• 关键词：Atazanavir ; Raltegravir ; HIV ; NRTI-sparing antiretroviral therapy ; Treatment-experienced patients
• 刊名：Journal of Clinical Virology
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：87
• 期：Complete
• 页码：30-36
• 全文大小：829 K
• 卷排序：87

文摘

RAL plus unboosted ATV is an option for NRTI- and RTV-sparing dual regimen. Of 102 patients observed, 77.5% had virological response after more than 2 years follow-up. A concerning rate (18.6%) failed with newly selected mutations. Safety and tolerability profile was confirmed, only 4 discontinued for intolerance. RAL plus ATV might be considered in selected adherent patients.